FDA extends review for AstraZeneca's (AZN) experimental breast cancer drug
The US Food and Drug Administration's decision to extend its review of AstraZeneca's experimental breast cancer drug, camizestrant, sent the company's shares down 3.2% on the London Stock Exchange today. AstraZeneca (AZN) is trading at 13,561p, following yesterday's close of 14,008p.
The delay, announced on May 27, 2026, allows the FDA to assess additional data, including circulating tumour DNA clearance data linked to longer-term efficacy outcomes. This information stems from the SERENA-6 Phase III trial, with full results scheduled for presentation at the American Society of Clinical Oncology (ASCO) meeting on June 2, 2026.
This extended review follows an April 2026 decision by the FDA's Oncologic Drugs Advisory Committee, which did not reach a majority vote to recommend switching patients to camizestrant in combination with a CDK4/6 inhibitor.
What an FDA Delay Means for AstraZeneca
AstraZeneca is a global pharmaceutical giant that develops, manufactures, and sells prescription medicines across several key therapeutic areas, including oncology, cardiovascular, renal, and respiratory diseases. Their business model revolves around extensive research and development to discover new drugs, navigating rigorous clinical trials, and securing regulatory approvals to bring these treatments to patients worldwide. They generate revenue by selling these patented medications to hospitals, clinics, and pharmacies.
Today's share price movement for AstraZeneca largely stems from the US Food and Drug Administration's decision to extend its review period for camizestrant, their experimental breast cancer drug. This delay, announced on 27 May 2026, allows the FDA to scrutinise additional data, specifically circulating tumour DNA clearance information linked to longer-term efficacy outcomes from the SERENA-6 Phase III trial. This regulatory caution follows an earlier April 2026 decision by an FDA advisory committee, which did not reach a majority to recommend the drug in combination with another treatment.
This extension of the review period has seen AstraZeneca's shares trade down 3.2% today, currently at 13,561p, from yesterday's close of 14,008p.
Think of it like a highly anticipated restaurant opening that suddenly gets its final health inspection pushed back. The restaurant is ready, the menu is set, but until the health authority gives the all-clear, it can't open its doors and start serving customers. The delay itself isn't a rejection, but it pushes back the potential for revenue and adds an element of uncertainty for investors.
AstraZeneca
AstraZeneca PLC (AZN) is a biopharmaceutical firm engaged in the discovery, development, production, and commercialisation of prescription medications. Its extensive product portfolio spans oncology, cardiovascular, renal, and metabolic diseases, respiratory and immunology, and rare diseases. Key offerings include Tagrisso for oncology, Farxiga/Forxiga for cardiovascular health, and Symbicort for respiratory conditions. AstraZeneca also produces vaccines for COVID-19 and influenza, alongside treatments for gastroenterology and schizophrenia. The company distributes its products to primary and specialty care physicians globally through a network of distributors and local offices across the UK, Europe, the Americas, Asia, Africa, and Australasia. Founded in 1992, AstraZeneca PLC is headquartered in Cambridge, United Kingdom.